drugset
drugset / Trial / NCT07189403

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

NCT07189403 ↗

Phase 1 Recruiting 40 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Timeline

Start
2025-11-04
Primary completion
2028-03-01
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DS9051b Unknown — Oral

Indications

adrenal cortex carcinoma castration-resistant prostate carcinoma